Hepatocellular Carcinoma LINC01116 Outcompetes T Cells for Linoleic Acid and Accelerates Tumor Progression

Area of Science:

• Molecular Biology
• Cancer Research
• Immunology

Background:

• Hepatocellular carcinoma (HCC) exhibits an immunosuppressive tumor microenvironment and altered hepatic lipid metabolism.
• Long non-coding RNAs (lncRNAs) regulate gene expression, but their role bridging the tumor microenvironment and lipid metabolism is unclear.

Purpose of the Study:

• To identify and characterize a novel lncRNA involved in HCC progression and its immunometabolic role.
• To elucidate the molecular mechanism by which this lncRNA influences the tumor microenvironment and lipid metabolism.

Main Methods:

• Identification and validation of LINC01116 in HCC patients and preclinical models.
• Investigation of the LINC01116 mechanism involving EWSR1, RAD18, PPARA, and FABP1.
• Assessment of LINC01116 blockade in combination with anti-PD1 therapy in a preclinical HCC model.

Main Results:

• LINC01116 is upregulated in HCC and promotes tumor progression by stabilizing EWSR1.
• EWSR1 upregulates PPARA and FABP1, leading to cancer cell competition for long-chain fatty acids (LCFAs) and T cell dysfunction.
• Blocking LINC01116 enhances anti-PD1 therapy, increasing cytotoxic T cells and decreasing exhausted T cells.

Conclusions:

• LINC01116 acts as an immunometabolic lncRNA in HCC, linking lipid metabolism to immune evasion.
• The LINC01116-EWSR1-PPARA-FABP1 axis represents a potential therapeutic target for HCC immunotherapy.